Tigecycline
3074A1-900
Approved small_molecule completed
Quick answer
Tigecycline for Skin Diseases, Bacterial is a Approved program (small_molecule) at Wyeth is now a wholly owned subsidiary of Pfizer with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Wyeth is now a wholly owned subsidiary of Pfizer
- Indication
- Skin Diseases, Bacterial
- Phase
- Approved
- Modality
- small_molecule
- Status
- completed